BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 35180847)

  • 21. Molecular Characteristics of Pancreatic Ductal Adenocarcinomas with High-Grade Pancreatic Intraepithelial Neoplasia (PanIN) Are Different from Those without High-Grade PanIN.
    Miyazaki T; Ohishi Y; Miyasaka Y; Oda Y; Aishima S; Ozono K; Abe A; Nagai E; Nakamura M; Oda Y
    Pathobiology; 2017; 84(4):192-201. PubMed ID: 28291966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
    Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
    Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
    Dunne RF; Hezel AF
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):595-608. PubMed ID: 26226899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
    Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
    Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
    Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
    Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
    Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
    Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes.
    Lu J; Yu R; Liu R; Liang X; Sun J; Zhang H; Wu H; Zhang Z; Shao YW; Guo J; Liang Z
    Cancer Med; 2021 Feb; 10(3):933-943. PubMed ID: 33350171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.
    Masugi Y; Takamatsu M; Tanaka M; Hara K; Inoue Y; Hamada T; Suzuki T; Arita J; Hirose Y; Kawaguchi Y; Nakai Y; Oba A; Sasahira N; Shimane G; Takeda T; Tateishi K; Uemura S; Fujishiro M; Hasegawa K; Kitago M; Takahashi Y; Ushiku T; Takeuchi K; Sakamoto M;
    J Pathol Clin Res; 2023 Sep; 9(5):339-353. PubMed ID: 37291757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer.
    Zhang X; Mao T; Zhang B; Xu H; Cui J; Jiao F; Chen D; Wang Y; Hu J; Xia Q; Ge W; Li S; Yue M; Ma J; Yao J; Wang Y; Wang Y; Shentu D; Zhang X; Chen S; Bai Y; Wang Y; Zhang X; Liu Q; Sun Y; Fu D; Liu Y; Xiong L; Wang L
    EBioMedicine; 2022 Mar; 77():103897. PubMed ID: 35231699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas.
    Gkountakos A; Mafficini A; Lou E; Malleo G; Salvia R; Calicchia M; Silvestris N; Racila E; Amin K; Veronese N; Brunetti O; Antonini P; Ingravallo G; Mattiolo P; Saponaro C; Nappo F; Simbolo M; Bariani E; Lonardi S; Fassan M; Milella M; Lawlor RT; Scarpa A; Luchini C
    Hum Pathol; 2022 Oct; 128():124-133. PubMed ID: 35850360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
    Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
    Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic sequencing of key genes in mouse pancreatic cancer cells.
    Wang Y; Zhang Y; Yang J; Ni X; Liu S; Li Z; Hodges SE; Fisher WE; Brunicardi FC; Gibbs RA; Gingras MC; Li M
    Curr Mol Med; 2012 Mar; 12(3):331-41. PubMed ID: 22208613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
    ;
    Cancer Cell; 2017 Aug; 32(2):185-203.e13. PubMed ID: 28810144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative genomic analysis of head and body/tail of pancreatic ductal adenocarcinoma at early and late stages.
    Zhang X; Feng S; Wang Q; Huang H; Chen R; Xie Q; Zhang W; Wang A; Zhang S; Wang L; Yao M; Ling Q
    J Cell Mol Med; 2021 Feb; 25(3):1750-1758. PubMed ID: 33452856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
    Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
    Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular characterisation of pancreatic ductal adenocarcinoma with
    Allen MJ; Zhang A; Bavi P; Kim JC; Jang GH; Kelly D; Perera S; Denroche RE; Notta F; Wilson JM; Dodd A; Ramotar S; Hutchinson S; Fischer SE; Grant RC; Gallinger S; Knox JJ; O'Kane GM
    J Clin Pathol; 2023 Mar; 76(3):158-165. PubMed ID: 34583947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.